Entellus Medical, Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $19.78, for a total value of $791,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Brian E. Farley also recently made the following trade(s):

  • On Tuesday, October 3rd, Brian E. Farley sold 6,028 shares of Entellus Medical stock. The shares were sold at an average price of $19.17, for a total value of $115,556.76.
  • On Monday, October 2nd, Brian E. Farley sold 3,972 shares of Entellus Medical stock. The shares were sold at an average price of $19.10, for a total value of $75,865.20.

Shares of Entellus Medical, Inc. (NASDAQ:ENTL) traded up 2.82% during midday trading on Wednesday, hitting $20.05. The company had a trading volume of 219,809 shares. The company’s market capitalization is $508.69 million. Entellus Medical, Inc. has a 12-month low of $12.31 and a 12-month high of $22.57. The company’s 50-day moving average price is $17.67 and its 200 day moving average price is $17.67.

Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings data on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The business had revenue of $22.10 million during the quarter, compared to analysts’ expectations of $21.87 million. During the same quarter in the prior year, the firm posted ($0.27) earnings per share. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. Equities research analysts predict that Entellus Medical, Inc. will post ($1.61) earnings per share for the current fiscal year.

WARNING: “Insider Selling: Entellus Medical, Inc. (ENTL) Director Sells 40,000 Shares of Stock” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/insider-selling-entellus-medical-inc-entl-director-sells-40000-shares-of-stock.html.

A number of large investors have recently made changes to their positions in ENTL. Swiss National Bank boosted its holdings in Entellus Medical by 98.9% in the 1st quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock valued at $244,000 after purchasing an additional 8,800 shares during the period. TD Asset Management Inc. bought a new position in Entellus Medical in the 1st quarter valued at $279,000. Parametric Portfolio Associates LLC boosted its holdings in Entellus Medical by 5.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after purchasing an additional 573 shares during the period. Royce & Associates LP boosted its holdings in Entellus Medical by 288.4% in the 1st quarter. Royce & Associates LP now owns 167,000 shares of the medical technology company’s stock valued at $2,305,000 after purchasing an additional 124,000 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Entellus Medical by 77.8% in the 1st quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock valued at $5,862,000 after purchasing an additional 185,833 shares during the period. 70.24% of the stock is owned by hedge funds and other institutional investors.

ENTL has been the subject of several recent research reports. Piper Jaffray Companies reiterated a “buy” rating and issued a $21.00 price target on shares of Entellus Medical in a research note on Tuesday, August 22nd. BidaskClub upgraded Entellus Medical from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. Finally, Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $21.71.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.